Item Details
Eli Lilly signs cancer research partnership worth up to $5.9 billion
Announced on 16 November, Eli Lilly has signed a research and licensing agreement with Cambridge based Stipple Bio to develop targeted cancer treatments. The agreement could be worth up to $5.9 billion through milestone payments and royalties. HPC could help connect biotechnology companies with pharmaceutical groups, research partners and investors.
Get in Touch
We’ll get back to you shortly.